HGEN · Humanigen, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $2.51M | $3.60M | $312.0K | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $55.21M | $213.12M | $72.71M | $2.62M | $2.22M | $11.16M |
| SG&A | $15.61M | $23.25M | $15.80M | $6.33M | $9.11M | $7.87M |
| Total Operating Expenses | $70.82M | $236.37M | $88.51M | $8.94M | $11.33M | $19.03M |
| D&A | - | - | - | - | $19.0K | $48.0K |
| Operating Income | ($68.30M) | ($232.77M) | ($88.20M) | ($8.94M) | ($11.33M) | ($19.03M) |
| Interest Expense | $2.92M | $2.26M | $1.34M | $1.35M | $852.0K | $3.06M |
| Income Tax | - | $21.60M | - | - | - | - |
| Net Income | ($70.73M) | ($236.65M) | ($89.53M) | ($10.29M) | ($12.00M) | ($21.99M) |
| EPS - Basic | ($4.04) | - | - | - | - | - |
| EPS - Diluted | ($4.04) | - | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.15M | $70.02M | $67.74M | $143.0K | $814.0K | $737.0K |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $40.52M | $44.70M | $13.08M | $5.05M | $2.86M | $3.33M |
| Current Assets | $11.11M | $70.97M | $68.21M | $452.0K | $1.30M | $1.55M |
| Total Assets | $11.20M | $71.06M | $68.30M | $523.0K | $1.37M | $1.67M |
| Current Liabilities | $56.19M | $68.72M | $20.41M | $13.59M | $8.26M | $24.66M |
| Long-term Debt | - | $25.01M | - | $6.49M | - | - |
| Total Liabilities | $57.96M | $94.75M | $22.76M | $14.84M | $9.48M | $26.01M |
| Stockholders' Equity | ($46.77M) | ($23.69M) | $45.55M | ($14.32M) | ($8.11M) | ($24.34M) |
| Retained Earnings | ($681.81M) | ($611.08M) | ($374.43M) | ($284.89M) | ($274.60M) | ($262.60M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($76.70M) | ($184.04M) | ($69.85M) | ($4.00M) | ($6.21M) | ($20.96M) |
| Investing Cash Flow | - | - | ($20.0K) | - | - | $103.0K |
| Financing Cash Flow | $16.84M | $186.32M | $137.47M | $3.33M | $6.26M | $15.33M |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -2716.9% | -6474.9% | -28268.6% | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | -2813.4% | -6582.7% | -28697.1% | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | 2196.1% | 5928.1% | 23305.4% | - | - | - |
| SG&A / Revenue | 620.8% | 646.8% | 5063.1% | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -631.8% | -333.0% | -131.1% | -1968.3% | -876.2% | -1316.6% |
| Return on equity | 151.2% | 999.0% | -196.6% | 71.9% | 148.0% | 90.3% |
| Return on invested capital | - | -13952.2% | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.20 | 1.03 | 3.34 | 0.03 | 0.16 | 0.06 |
| Quick ratio | 0.20 | 1.03 | 3.34 | 0.03 | 0.16 | 0.06 |
| Cash ratio | 0.18 | 1.02 | 3.32 | 0.01 | 0.10 | 0.03 |
| Leverage | ||||||
| Debt / Equity | - | -1.06 | - | -0.45 | - | - |
| Debt / Assets | - | 0.35 | - | 12.40 | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -23.4x | -102.8x | -66.0x | -6.6x | -13.3x | -6.2x |
| Equity multiplier | -0.24 | -3.00 | 1.50 | -0.04 | -0.17 | -0.07 |
| Liabilities / Assets | 5.18 | 1.33 | 0.33 | 28.38 | 6.92 | 15.57 |
| Efficiency | ||||||
| Asset turnover | 0.22 | 0.05 | 0.00 | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -30.1% | 1052.2% | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 70.7% | -163.9% | -886.1% | 21.1% | 40.5% | -1.1% |
| Net income growth (YoY) | 70.1% | -164.3% | -769.8% | 14.2% | 45.4% | 18.6% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -97.4% | - | - | -76.5% | 66.7% | -455.7% |
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-73.54
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing HUMANIGEN against the 5 most active filers in the same SIC group.